HealthDay Reporter
WEDNESDAY, Nov. 17, 2021 (HealthDay News) -- The archetypal quality clinical trial of a nasal vaccine to dilatory the progression of Alzheimer's disease is acceptable to statesman aft astir 20 years of research.
This is simply a "remarkable milestone," according to Dr. Howard Weiner, co-director of the Ann Romney Center for Neurologic Diseases astatine Brigham and Women's Hospital successful Boston.
"Over the past 2 decades, we've amassed preclinical grounds suggesting the imaginable of this nasal vaccine for AD [Alzheimer's disease]," Weiner said successful a infirmary quality release. "If objective trials successful humans amusement that the vaccine is harmless and effective, this could correspond a nontoxic attraction for radical with Alzheimer's, and it could besides beryllium fixed aboriginal to assistance forestall Alzheimer's successful radical astatine risk."
The vaccine features an experimental cause called Protollin that stimulates the immune system. It's designed to punctual achromatic blood cells successful the lymph nodes connected the sides and backmost of the cervix to migrate to the encephalon and wide beta amyloid plaques, a hallmark of Alzheimer's disease.
According to Dr. Tanuja Chitnis, main researcher successful the trial, "For 20 years, determination has been increasing grounds that the immune strategy plays a cardinal relation successful eliminating beta amyloid. This vaccine harnesses a caller limb of the immune strategy to dainty AD." Chitnis is simply a prof of neurology astatine the hospital.
"Research successful this country has paved the mode for america to prosecute a full caller avenue for perchance treating not lone AD, but besides different neurodegenerative diseases," she added.
The signifier 1 proceedings volition see 16 patients betwixt 60 and 85 years of property who person early, symptomatic Alzheimer's illness but are different successful bully wide health. They volition person 2 doses of the nasal vaccine 1 week apart.
Along with assessing the vaccine's information and however good patients tolerate it, the researchers volition analyse however it affects immune response, including its interaction connected achromatic humor cells.
The proceedings is funded by I-Mab Biopharma and Jiangsu Nhwa Pharmaceutical, developers and makers of Protollin.
More information
The Alzheimer's Association has much connected Alzheimer's disease.
SOURCE: Brigham and Women's Hospital, quality release, Nov. 16, 2021
English (US) ·